INQUELOR
Sanofi Biotechnology
| Research |
OneLook
Acronym Finder
|
| Serial Number | 86871817 |
| Registration Number | 4993504 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Domestic Representative | Karen Lim |
| Attorney Name | Karen Lim |
| Attorney Docket Number | SYNB 1600212 |
| Law Office Assigned | M60 |
| Employee Name | DEFORD, JEFFREY S |
Timeline
| 2016-01-11 | Application Filed |
| 2016-04-19 | Published for Opposition |
| 2016-07-05 | Location: PUBLICATION AND ISSUE SECTION |
| 2016-07-05 | Status: Live/Registered |
| 2016-07-05 | Trademark Registered |
| 2020-01-08 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  Sanofi Biotechnology |
| Address | 54, rue La Boétie Paris FR 75008 |
| Legal Entity Type | Corporation |
| Legal Entity State | FR |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations for the treatment of allergies and allergic diseases and disorders, autoimmune diseases and disorders, dermatological diseases and disorders, damaged skin and tissues, gastrointestinal diseases and disorders, inflammation and inflammatory diseases and disorders, respiratory diseases and disorders |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2016-01-14 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2016-01-18 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2016-02-22 | 3 DOCK D:Assigned to Examiner |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2016-02-23 | 4 CNSA O:Outgoing Correspondence |
| ASSIGNED TO LIE | 2016-03-14 | 5 ALIE A:Allowance for Publication |
| LAW OFFICE PUBLICATION REVIEW COMPLETED | 2016-03-15 | 6 PREV O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2016-03-30 | 7 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2016-04-19 | 8 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2016-04-19 | 9 NPUB E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2016-07-05 | 10 R.PR A:Allowance for Publication |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2017-01-31 | 11 CRFA I:Incoming Correspondence |
| REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED | 2017-04-05 | 12 CORV 1: |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-12-10 | 13 CRFA I:Incoming Correspondence |
| REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED | 2020-01-08 | 14 CORV 1: |
| COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | 2021-07-05 | 15 REM1 E:E-Mail |
| CANCELLED SEC. 8 (6-YR) | 2023-01-20 | 16 C8.. O:Outgoing Correspondence |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 INQUELOR 86871817 4993504 Live/Registered |
Sanofi Biotechnology 2016-01-11 |
 INQUELOR 86728599 not registered Dead/Abandoned |
SANOFI BIOTECHNOLOGY 2015-08-18 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 